understand
human
diseas
potenti
therapeut
improv
rapidli
order
take
advantag
develop
import
abl
identifi
diseas
marker
mani
new
highthroughput
genom
proteom
technolog
implement
identifi
candid
diseas
marker
technolog
includ
protein
microarray
nextgener
dna
sequenc
mass
spectrometri
platform
method
particularli
import
elucid
repertoir
molecular
marker
genom
transcriptom
proteom
metabolom
patient
diseas
cancer
autoimmun
diseas
viral
infect
result
disrupt
mani
biolog
pathway
new
technolog
identifi
mani
potenti
diseas
marker
marker
expect
valuabl
achiev
promis
truli
person
medicin
diseas
marker
vital
import
clinician
patient
earli
detect
accur
prognosisdiagnosi
monitor
therapi
lead
increas
overal
surviv
cure
rate
knowledg
diseas
quickli
expand
field
diseas
marker
discoveri
play
increasingli
import
role
deliveri
improv
diagnosi
treatment
marker
protein
includ
autoantibodi
antibodi
specif
selfantigen
hormon
marker
lack
insulin
type
diabet
patient
geneticgenom
marker
mutat
breast
cancer
patient
enabl
clinician
diagnos
diseas
still
earli
stage
ensur
appropri
surgic
intervent
effici
drug
treatment
monitor
predict
individu
risk
develop
specif
diseas
experi
symptom
tradit
discoveri
detect
diseas
marker
reli
low
throughput
technolog
enzymelink
immunosorb
assay
elisa
plu
edman
degrad
protein
marker
revers
transcriptionpolymeras
chain
reaction
rtpcr
mrna
marker
restrict
enzym
digest
clone
sanger
sequenc
dna
marker
dawn
highthroughput
technolog
method
play
import
role
marker
identif
yield
signific
discoveri
variou
diseas
system
lupu
erythematosi
rheumatoid
arthriti
breast
cancer
greatli
enhanc
diagnost
effici
diseas
past
two
decad
highthroughput
technolog
emerg
display
great
potenti
largescal
studi
marker
discoveri
technolog
includ
protein
microarray
mass
spectrometri
largescal
shotgun
studi
recent
highthroughput
parallel
sequenc
includ
rnasequenc
articl
review
diseas
marker
discoveri
use
system
biolog
approach
focu
highdens
protein
microarray
technolog
also
briefli
review
current
progress
diseas
marker
identif
use
parallel
sequenc
mass
spectrometri
technolog
current
highdens
protein
microarray
contain
hundr
thousand
protein
array
coat
glass
microscop
slide
eg
nitrocelluloseco
slide
address
format
array
usual
probe
fluoresc
label
molecul
signal
acquir
confoc
laser
scanner
number
surfac
chemistri
employ
abil
bind
protein
effici
although
often
tradeoff
retent
decreas
protein
function
improp
fold
sever
broad
categori
protein
microarray
array
compos
cell
tissu
lysat
protein
fraction
isol
crude
lysat
antibodi
analyt
array
contain
type
antibodi
direct
specif
analyt
well
socal
function
protein
array
function
protein
array
contain
full
length
protein
intact
catalyt
function
proper
epitop
fold
often
gener
array
purifi
protein
produc
individu
prior
print
protein
produc
situ
vitro
transcript
translat
dna
print
directli
surfac
array
group
develop
last
type
protein
microarray
array
purifi
protein
nitrocelluloseco
glass
slide
type
function
protein
microarray
clear
advantag
altern
abil
specif
identifi
individu
protein
compar
cell
lysat
array
abil
ensur
qualiti
array
protein
compar
situ
transcriptiontransl
array
develop
first
protein
microarray
contain
fulllength
protein
bud
yeast
saccharomyc
cerevisia
group
produc
number
protein
array
includ
yeast
ntermin
ctermin
array
protein
arabidopsi
array
coronaviru
array
conjunct
protometrix
corpor
part
invitrogen
corpor
also
collabor
develop
human
protein
array
current
hold
protein
express
individu
use
express
system
variou
array
use
varieti
applic
includ
assay
proteinprotein
proteinlipid
proteinnucl
acid
interact
well
probe
substrat
protein
kinas
also
develop
algorithm
posit
signal
call
larg
dataset
process
recent
appli
technolog
novel
proteomicsbas
approach
screen
human
antibodi
react
foreign
selfantigen
particularli
notabl
review
use
protein
microarray
analyz
immun
respons
coronavirus
well
screen
project
analyz
ovarian
cancer
myeloma
multipl
sclerosi
asthma
section
review
diseas
marker
identif
sever
field
use
highdens
protein
microarray
current
test
detect
microbi
infect
clinic
test
reli
measur
antibodi
respons
elisabas
detect
method
often
use
detect
patient
antibodi
titer
epitop
microorgan
diagnosi
infect
late
outbreak
novel
coronaviru
cov
sever
acut
respiratori
syndrom
sar
viru
result
kill
death
novel
diagnost
test
requir
identifi
monitor
diseas
elisa
immunofluoresc
nucleic
acid
test
employ
shown
protein
arraybas
method
prove
accur
exist
antibodi
base
method
lab
develop
coronaviru
proteinmicroarray
contain
coronaviru
protein
includ
sarscov
protein
protein
five
addit
coronavirus
microarray
use
probe
sera
obtain
canadian
chines
sar
outbreak
includ
sampl
confirm
sarscov
case
respiratori
diseas
patient
healthcar
profession
detect
antihuman
igg
antibodi
bound
reactiv
antibodi
coronavirusencod
protein
sera
visual
quantifi
reactiv
result
differ
protein
analyz
use
varieti
comput
method
develop
comput
algorithm
base
reactiv
result
predict
patient
infect
sar
protein
microarray
platform
display
high
sensit
reliabl
detect
sarscov
reactiv
antibodi
even
serum
dilut
fold
assay
show
good
reproduc
less
varianc
signal
intens
duplic
slide
importantli
method
requir
less
one
microlit
serum
detect
desir
serum
sampl
limit
moreov
probe
coronaviru
protein
microarray
sar
infect
serum
sampl
also
show
high
specif
sarscovspecif
protein
littl
crossreact
protein
coronavirus
observ
sar
infect
serum
sampl
determin
best
classifi
distinguish
sarsposit
sarsneg
sera
use
one
unsupervis
cluster
method
two
supervis
method
knearest
neighbor
knn
logist
regress
lr
supervis
model
show
high
sensit
knn
lr
specif
knn
lr
panel
knn
lr
best
classifi
number
greater
assay
perform
triplic
predict
method
test
sera
chines
fever
patient
sarsinfect
predict
determin
sensit
specif
superior
two
elisabas
detect
method
use
sar
outbreak
studi
sarscov
infect
diagnosi
via
detect
sarscovspecif
antibodi
protein
microarray
demonstr
approach
sensit
sensit
elisa
specif
littl
crossreact
coronaviru
protein
rapid
perform
hour
nevertheless
note
test
base
immun
respons
foreign
antigen
like
achiev
higher
accuraci
base
autoantibodyautoantigen
respons
sinc
selftoler
foreign
antigen
presenc
pathogen
associ
molecular
pattern
pamp
significantli
increas
immun
respons
overal
studi
demonstr
first
time
protein
microarray
could
use
diagnos
monitor
human
antibodi
protein
marker
gener
cours
diseas
moreov
demonstr
power
use
panel
multipl
classifi
diagnost
protein
microarray
technolog
effici
accur
detect
antibodi
gener
foreign
antigen
infecti
organ
perhap
intrigu
applic
technolog
discoveri
novel
protein
marker
earli
detect
variou
cancer
identif
diseas
marker
hold
promis
increas
effect
clinic
therapi
markerbas
routin
screen
program
potenti
enabl
diagnosi
earliest
stage
diseas
develop
clinic
recogniz
cancer
usual
advanc
stage
instanc
heavi
smoker
autoantibodi
recogn
mutant
form
tumor
suppressor
detect
prior
diagnosi
lung
cancer
earli
detect
treatment
would
result
markedli
improv
surviv
rate
especi
patient
whose
cancer
present
symptom
earli
stage
pancreat
ovarian
cancer
oncoproteom
rapidli
expand
field
aim
appli
highthroughput
proteom
approach
understand
mechan
involv
cancer
proteom
approach
discov
cancer
marker
area
strong
interest
recent
year
past
project
often
involv
serum
screen
phage
express
librari
prepar
cancer
tissu
serex
serolog
analysi
cdna
express
librari
immunoblot
cancer
cell
lysat
two
dimension
polyacrylamid
gel
electrophoresi
approach
yield
promis
candid
marker
suffer
particular
issu
fact
phage
express
librari
often
contain
frame
truncat
protein
target
protein
candid
discov
difficult
identifi
sinc
protein
unknown
mass
spectrometri
often
requir
order
identifi
candid
autoantigen
addit
problem
approach
sampl
usual
limit
amount
difficult
reproduc
protein
microarray
overcom
difficulti
spot
protein
deriv
known
wellcharacter
clone
addit
even
small
amount
purifi
protein
suffici
print
hundr
array
patient
screen
tradit
diseas
marker
protein
becom
overor
underexpress
cours
diseas
much
interest
potenti
use
autoantibodi
novel
class
diseas
marker
recent
detect
serum
circul
autoantibodi
target
tumorassoci
antigen
taa
emerg
effect
approach
identifi
cancer
earli
detect
marker
eg
breast
lung
ductal
pancreat
cancer
approach
base
fact
immun
system
produc
antibodi
abnormalmut
protein
gener
apoptoticnecrot
cancer
cell
autoantibodi
detect
immunosorb
assay
like
elisa
levelsst
autoantibodi
potenti
much
greater
origin
autoantigen
would
easili
detect
compar
autoantibodi
profil
differ
group
cancer
patient
versu
control
possibl
identifi
marker
significantli
differenti
express
method
expect
superior
dna
arraybas
method
sinc
chang
rna
express
level
necessarili
correl
protein
express
area
research
autoantibodi
marker
discoveri
use
protein
microarray
rapidli
expand
last
sever
year
protein
array
platform
continu
matur
recent
avail
high
content
protein
microarray
allow
global
profil
autoantibodi
cancer
antigen
highthroughput
thousand
protein
candid
high
sensit
fg
protein
improv
print
techniqu
increas
protein
spot
quantiti
made
array
promis
vehicl
explor
repertoir
autoantibodi
human
diseas
approach
appli
variou
group
discoveri
autoantibodi
marker
breast
cancer
lung
cancer
ovarian
cancer
well
smaller
studi
pancreat
cancer
review
past
ongo
research
immun
respons
profil
use
protein
microarray
relat
number
diseas
state
selftoler
usual
abrog
antibodi
respons
selfprotein
possibl
elicit
autoimmun
respons
certain
condit
present
case
diseas
antigen
self
protein
may
result
overexpress
normal
protein
case
breast
cancer
subtyp
prostat
specif
antigen
psa
prostat
cancer
aberr
posttransl
modif
differ
glycoform
breast
cancer
mutat
protein
found
case
tumor
suppressor
multipl
cancer
type
addit
protein
usual
restrict
express
germ
line
cell
express
earli
stage
develop
may
aberrantli
express
cancer
case
testi
antigen
carcinoembryogen
antigen
cea
respect
mani
protein
mention
detect
low
level
serum
even
late
stage
diseas
would
littl
util
screen
purpos
howev
even
slight
increas
express
antigen
lead
detect
increas
correspond
autoantibodi
gener
find
exist
basal
autoantibodi
level
mani
selfantigen
howev
respons
shown
markedli
increas
case
diseas
mention
current
clinic
approv
marker
ovarian
cancer
screen
unfortun
although
serum
level
significantli
elev
advanc
stage
diseas
posit
predict
valu
detect
earli
stage
ovarian
cancer
less
reason
identif
new
marker
diseas
critic
import
scientist
group
led
gil
mor
yale
univers
recruit
proteomicsbas
approach
use
antibodybas
protein
microarray
identifi
new
serum
biomark
combin
may
enhanc
earli
detect
ovarian
cancer
group
also
launch
pilot
studi
profil
ovarian
cancerassoci
autoantibodi
protein
microarray
contain
fulllength
human
protein
compar
autoantibodi
profil
case
epitheli
ovarian
cancer
patient
healthi
control
statist
analysi
identifi
protein
significantli
differ
immun
reactiv
patient
group
versu
control
group
result
valid
immunohistochemistri
ihc
demonstr
high
sensit
specif
top
two
marker
lamin
ac
combin
howev
valid
requir
candid
marker
adopt
clinic
set
therefor
carri
top
rank
candid
valid
phase
much
larger
set
sampl
test
evalu
perform
potenti
marker
gener
focus
protein
microarray
contain
candid
well
control
protein
fig
array
print
twelv
block
per
slide
allow
mani
twelv
sampl
screen
per
array
approach
allow
hundr
thousand
sampl
screen
order
determin
marker
combin
marker
demonstr
best
receiv
oper
characterist
roc
perform
autoantigen
breast
cancer
subtyp
posit
tumor
shown
correl
increas
autoantibodi
respons
patient
autoantibodi
patient
demonstr
approxim
sensit
specif
group
adapt
similar
approach
multiplex
ing
immun
respons
use
highdens
protein
microarray
breast
cancer
among
studi
anderson
et
al
use
nucleic
acid
programm
protein
array
nappa
sera
screen
breast
cancer
array
gener
print
individu
gene
plasmid
dna
along
captur
antibodi
gst
tag
fusion
protein
array
incub
vitro
transcript
translat
coupl
cellfre
lysat
produc
protein
anchor
array
surfac
array
consist
cancer
associ
candid
protein
includ
well
epstein
bar
nuclear
antigen
ebna
control
sera
four
breast
cancer
patient
four
healthi
control
use
probe
array
found
autoantibodi
cancer
patient
protein
produc
array
readi
probe
suffer
degrad
period
storag
howev
protein
quantiti
variabl
spot
compar
directli
print
array
found
spot
spot
variat
protein
amount
may
overcom
evalu
autoantibodi
respons
rel
protein
amount
ie
ratio
autoantibodi
signal
signal
epitop
tag
autoantigen
protein
array
immun
respons
profil
studi
found
approach
result
decreas
signal
varianc
replic
spot
unpublish
data
date
studi
attempt
identifi
novel
breast
cancer
marker
perform
use
highdens
protein
microarray
previou
highthroughput
serum
screen
breast
cancer
reli
serex
involv
rel
small
sampl
set
interest
immun
respons
profil
studi
may
autoantibodi
respons
selfantigen
cancer
blood
lymph
multipl
myeloma
lab
involv
protein
microarray
base
screen
project
aim
elucid
autoantigen
repertoir
multipl
myeloma
multipl
myeloma
cancer
bone
marrow
system
result
uncontrol
prolifer
monoclon
plasma
cell
precursor
bcell
respons
product
antibodi
monoclon
gammopathi
unspecifi
signific
mgu
precursor
diseas
multipl
myeloma
character
bone
marrow
plasmacytosi
increas
mprotein
level
blood
probe
highdens
protein
array
use
plasma
dozen
case
mgu
multipl
myeloma
healthi
control
compar
igg
respons
individu
antigen
array
healthi
diseas
group
identifi
multipl
autoantigen
significantli
differenti
target
igg
autoantibodi
earli
stage
diseas
studi
uniqu
employ
highest
densiti
protein
array
multipl
myeloma
immun
respons
profil
date
patient
sampl
prospect
collect
sampl
drawn
prior
diseas
onset
artifact
result
medic
treatment
patient
queri
earli
stage
sampl
better
chanc
identifi
marker
effect
diagnos
patient
earli
stage
treatabl
experi
better
outcom
marker
identifi
studi
may
yield
insight
biolog
process
mutat
event
contribut
develop
aggress
form
multipl
myeloma
addit
earli
detect
cancer
marker
may
also
enabl
clinician
offer
person
treatment
recent
advanc
use
anticanc
drug
herceptin
iressa
illustr
point
drug
target
specif
patient
popul
herceptin
effect
tumor
express
receptor
iressa
effect
patient
specif
mutat
epiderm
growth
factor
receptor
drug
offer
limit
benefit
patient
cancer
type
marker
present
thu
determin
marker
profil
individu
diseas
enabl
identif
distinct
patient
popul
allow
tailor
effect
treatment
one
issu
would
like
note
singl
autoantibodi
respons
autoantigen
confirm
suffici
sensit
specif
screen
purpos
earli
stage
diseas
howev
evalu
antibodi
respons
involv
panel
autoantigen
accuraci
markedli
improv
thu
futur
protein
microarray
immun
respons
screen
test
like
combin
multipl
autoantigen
numer
approach
appli
combin
diseas
marker
common
method
combin
multipl
autoantibodi
respons
linear
regress
splitpoint
analysi
knearest
neighbor
knn
still
current
clinic
screen
diagnost
test
reli
panel
protein
marker
although
multiparamet
dna
microarray
test
becom
commonplac
diseas
breast
cancer
clearli
work
need
autoantigen
base
microarray
test
implement
clinic
set
use
protein
microarray
technolog
biomark
discoveri
autoimmun
diseas
seem
natur
extens
techniqu
autoantibodi
respons
alreadi
shown
contribut
diseas
progress
diseas
lupu
antinuclear
antibodi
test
sometim
use
confirm
diagnosi
certain
autoimmun
diseas
diseas
specif
multipl
sclerosi
ms
debilit
diseas
central
nervou
system
character
round
axon
demyelin
repair
affect
mostli
younger
peopl
common
women
men
underli
caus
remain
unknown
though
mount
evid
antibodi
respons
self
protein
play
role
demyelin
repair
previou
effort
identifi
number
myelin
specif
protein
demonstr
increas
autoantibodi
respons
ms
autoantibodi
detect
serum
cerebrospin
fluid
csf
recent
protein
microarray
screen
appli
evalu
autoantibodi
respons
subset
myelin
protein
known
associ
ms
neurodegen
diseas
antigen
shown
elicit
autoantibodi
respons
includ
classic
ms
antigen
myelinbas
protein
mbp
myelin
associ
glycoprotein
mag
myelin
oligodendrocyt
glycoprotein
mog
well
protein
demonstr
play
signific
role
ms
previous
studi
suffer
fact
array
focus
rel
small
number
previous
known
candid
autoantigen
group
current
conduct
largerscal
screen
base
highdens
protein
microarray
platform
tent
identifi
number
novel
candid
marker
multipl
sclerosi
current
work
valid
marker
larger
sampl
set
less
bias
approach
may
result
identif
novel
autoantigen
lead
better
understand
underli
mechan
etiolog
ms
result
improv
screen
diagnost
test
asthma
common
diseas
preval
age
children
year
age
unit
state
anoth
diseas
involv
autoimmun
mechan
heterogen
inflammatori
diseas
airway
mark
recurr
episod
airway
obstruct
wheez
anatom
character
bronchoconstrict
inflamm
thicken
airway
wall
consid
asthma
aberr
chronic
wound
heal
process
would
surpris
releasedleak
cellular
content
airway
epithelium
due
damag
remodel
similar
necrot
cancer
cell
may
elicit
autoimmun
fact
aberr
autoantibodi
detect
asthmat
sera
autolog
serum
skin
test
compar
normal
control
autoreact
antibodi
also
de
tect
asthmat
sera
highaffin
ige
receptor
specif
autoantigen
identifi
serum
asthmat
patient
includ
autoiggreact
receptor
cytokeratin
moreov
studi
atop
dermat
often
occur
asthma
reveal
autoreact
ige
antibodi
hom
hom
hom
hom
hom
protein
calciumbind
motif
hom
type
ii
cytokeratin
howev
studi
focus
small
patient
group
cross
valid
well
limit
number
potenti
target
investig
sinc
autoreact
igg
ige
may
involv
pathogenesi
asthma
conduct
largescal
screen
asthmaassoci
autoigg
ige
reactiv
autoantigen
use
protein
microarray
protein
candid
unpublish
data
first
largescal
studi
profil
asthmaassoci
autoantigen
result
greatli
improv
understand
role
autoimmun
etiolog
asthma
one
uniqu
featur
studi
order
maintain
uniform
probe
condit
multiplex
detect
autoreact
igg
autoreact
ige
serum
sampl
simultan
array
mixtur
antihuman
igg
ige
secondari
detect
antibodi
label
distinct
fluoresc
dye
result
suggest
protein
array
capabl
detect
igg
ige
reactiv
signal
distinct
emiss
channel
high
specif
nodetect
signal
bleed
across
channel
fig
similar
applic
protein
array
perform
studi
autoimmun
diseas
song
et
al
discov
novel
autoantigen
name
albalik
dutpas
autoimmun
hepat
aih
use
protein
microarray
contain
nonredund
protein
horn
et
al
profil
repertoir
igg
autoantibodi
plasma
sampl
dilat
cardiomyopathi
dcm
patient
redund
protein
microarray
contain
total
protein
identifi
autoreact
protein
igg
reactiv
specif
subclass
autoantigen
also
identifi
chronic
diseas
alopecia
areata
protein
microarray
technolog
exampl
demonstr
great
potenti
protein
microarray
technolog
applic
autoantigen
marker
identif
autoimmun
diseas
although
protein
microarray
technolog
provid
highthroughput
method
high
sensit
specif
protein
marker
discoveri
particular
limit
investig
need
awar
appli
technolog
research
first
probe
protein
microarray
autoantibodi
vitro
studi
protein
target
array
platform
one
take
consider
offtarget
bind
therefor
find
protein
microarray
screen
valid
larger
sampl
set
autoantigen
confirm
direct
detect
method
western
blot
elisa
ihc
patient
sampl
autoantigen
confid
associ
diseas
secondli
microarray
contain
fulllength
fold
protein
may
recogn
autoantibodi
direct
misfold
degrad
protein
express
diseas
case
contribut
fals
neg
detect
patwa
et
al
develop
method
chemic
digest
protein
cnbr
print
array
may
help
overcom
problem
howev
digest
rate
hard
control
final
complex
mixtur
digest
protein
differ
level
may
complic
normal
effort
experiment
control
normal
array
data
anoth
import
consider
alreadi
discuss
normal
protein
spot
morpholog
quantiti
achiev
probe
label
antibodi
direct
epitopetag
appear
array
protein
eg
gst
variou
softwar
base
method
adopt
adjust
region
defect
background
tradit
issu
protein
dna
base
microarray
nevertheless
analysi
interpret
acquir
largescal
data
still
challeng
biologist
statistician
therefor
develop
improv
algorithm
ongo
effort
real
probe
condit
uncontrol
event
scratch
slide
deposit
salt
nonhomogen
local
concentr
complic
analysi
array
data
although
intern
control
often
includ
help
overcom
defect
improv
array
surfac
chemistri
significantli
decreas
local
region
background
defect
recent
year
becom
feasibl
sequenc
entir
genom
transcriptom
use
massiv
parallel
sequenc
platform
solexa
genom
analyz
platform
use
highli
sensit
light
sensor
cmo
sensor
ccd
camera
captur
fluoresc
signal
emit
deoxynucleotid
ad
dna
chain
simultan
million
parallel
reaction
flowcel
thu
perform
sequenc
highthroughput
manner
obtain
short
sequenc
vari
bp
depend
platform
one
end
current
relat
platform
product
avail
illumina
ig
appli
biosystem
solid
roch
life
scienc
helico
bioscienc
tsm
anoth
compani
pacif
bioscienc
manufactur
new
sequenc
perform
singl
molecul
sequenc
end
typic
parallel
sequenc
procedur
consist
follow
step
dnarna
isol
fragment
dnacdna
librari
construct
highthroughput
sequenc
read
assembl
map
method
mani
advantag
compar
tradit
tile
microarray
hybridizationbas
method
tradit
rtpcr
sanger
sequenc
method
new
platform
achiev
singlebas
resolut
highthroughput
manner
low
background
crosshybrid
nois
low
depend
avail
exist
genom
sequenc
high
reproduc
low
cost
per
base
upper
limit
quantif
section
briefli
review
recent
effort
genet
marker
discoveri
nextgener
parallel
sequenc
new
gener
sequenc
technolog
shape
new
paradigm
diseas
marker
research
massiv
amount
sequenc
inform
genom
dna
express
librari
screen
linkag
associ
genet
genom
marker
specif
diseas
compar
diseas
patient
healthi
individu
genom
dna
sequenc
provid
rich
inform
genet
variat
singl
nucleotid
polymorph
insert
delet
structur
variat
copi
number
variat
transposit
transloc
investig
genom
power
tool
reveal
novel
diseaseassoci
marker
genom
sequenc
also
detect
integr
viral
sequenc
may
help
address
studi
virusassoci
diseas
whole
genom
sequenc
alreadi
appli
organ
small
genom
acinetobact
baumannii
toxoplasma
gondii
drosophila
melanogast
howev
due
larg
size
human
genom
high
cost
parallel
sequenc
human
whole
genom
sequenc
still
infanc
ley
et
al
first
sequenc
entir
genom
one
type
cancer
tissu
acut
myeloid
leukemia
aml
cell
haploid
coverag
well
correspond
normal
tissu
patient
skin
tissu
haploid
coverag
due
unbias
natur
sequenc
method
abl
use
read
frequenc
establish
rate
mutat
vari
within
cancer
tissu
concept
import
futur
work
seek
understand
progress
mutat
event
lead
develop
diseas
like
cancer
research
found
singl
nucleotid
variat
uniqu
cancer
tissu
sampl
mutat
result
chang
code
region
ten
gene
two
previous
implic
cancer
nonetheless
sequenc
cost
continu
decreas
matur
platform
whole
genom
sequenc
larger
sampl
set
shed
light
new
venu
genet
genom
marker
identif
variou
diseas
biologist
clinician
prepar
come
revolut
project
alreadi
conceiv
clinseq
pilot
project
led
green
et
al
current
enrol
particip
whole
genom
sequenc
whole
transcriptom
sequenc
rna
sequenc
rnaseq
anoth
promis
applic
parallel
sequenc
technolog
alreadi
appli
marker
discoveri
variou
cancer
gene
express
profil
shown
predict
outcom
breast
type
cancer
shah
et
al
use
pair
end
rnaseq
canva
transcriptom
four
granulosecel
tumor
gct
ovarian
cancer
patient
found
common
missens
mutat
gene
tumor
present
ovarian
cancer
transcriptom
also
sequenc
addit
mutat
confirm
present
gct
cancer
test
leven
et
al
perform
illumina
sequenc
tilingarrayhybrid
enrich
transcript
repres
cancer
associ
gene
chronic
myeloid
leukemia
cell
line
detect
wide
rang
dna
rna
sequenc
alter
target
transcript
alter
includ
fusion
transcript
well
snp
within
splice
isoform
transcript
whole
genom
sequenc
still
rel
expens
proposit
transcriptom
sequenc
perform
much
lower
cost
facilit
discoveri
mutat
transcriptom
may
contribut
develop
diseas
addit
rna
sequenc
also
provid
inform
would
obtain
whole
genom
sequenc
inform
express
level
transcript
altern
splice
rna
edit
well
transsplic
event
expect
see
genet
genom
biomark
identifi
caus
contribut
factor
human
diseas
near
futur
thank
util
rna
sequenc
one
promis
applic
transcriptom
sequenc
identifi
virus
host
sampl
studi
carri
sorber
et
al
author
success
detect
hepat
b
viru
hbv
sequenc
serum
sampl
patient
hbv
infect
similarli
palacio
et
al
use
rnaseq
identifi
novel
old
world
arenaviru
rna
sampl
extract
liver
kidney
three
deceas
patient
transplantationrel
infect
nakamura
et
al
obtain
read
influenza
viru
sequenc
nasopharyng
aspir
read
noroviru
sequenc
fecal
specimen
patient
suffer
influenza
noroviru
infect
meanwhil
rwahnih
et
al
sequenc
rna
grapevin
roch
system
reveal
infect
plant
virus
well
one
novel
viru
diseas
grapevin
group
also
carri
rnaseq
experi
detect
west
nile
viru
sequenc
infect
macrophag
unpublish
data
obtain
read
total
map
read
map
west
nile
viru
genom
infect
cell
read
total
map
read
map
viral
sequenc
rna
isol
mock
control
cell
analysi
recheck
read
map
viru
genom
control
cell
found
redund
sequenc
human
genom
studi
prove
rnaseq
achiev
high
sensit
specif
identifi
profil
infect
virus
virom
use
rna
sampl
isol
host
moreov
rnaseq
also
provid
inform
virushost
interact
monitor
express
chang
host
gene
mutat
proteincod
sequenc
well
known
contribut
multipl
diseas
rnaseq
limit
activ
transcrib
sequenc
genom
bia
result
overlook
variat
nontranscrib
region
genom
import
contributor
diseas
mutat
region
result
aberr
gene
regul
besid
whole
genom
sequenc
chipseq
chromatin
immunoprecipitationsequenc
anoth
approach
address
mutat
function
nontranscrib
region
genom
technolog
sequenc
genom
region
bound
transcript
factor
dnabind
protein
histon
provid
inform
posit
bind
site
well
possibl
mutat
site
bind
site
profil
multipl
transcript
factor
well
identifi
sequenc
variat
within
may
act
new
marker
diseas
leukemia
sonoseq
relat
technolog
develop
lab
parallel
sequenc
sonic
formaldehyd
crosslink
chromatin
dna
via
illumina
sequenc
identifi
chromatin
region
open
access
nucleosomefre
therefor
suscept
sonic
technolog
identifi
multipl
highli
access
chromatin
region
includ
activ
transcrib
promot
region
well
ctcf
insul
protein
bind
site
technolog
similar
anoth
open
chromatin
find
technolog
term
fair
formaldehydeassist
isol
regulatori
element
select
open
chromatin
region
dna
microarray
hybrid
phenolchloroform
extract
sonic
crosslink
sampl
interrog
background
diseas
compar
healthi
control
identifi
profil
nucleosomefre
region
may
provid
new
type
diseas
marker
futur
studi
nextgener
sequenc
hold
great
promis
discoveri
novel
diseas
marker
issu
current
technolog
artifact
due
sampl
prepar
revers
transcript
polymeras
chain
reaction
gener
bias
data
process
assembl
short
read
result
error
especi
region
repetit
sequenc
newer
technolog
compani
like
helico
bioscienc
pacif
bioscienc
horizon
could
overcom
issu
direct
rna
sequenc
long
singl
molecul
sequenc
fulfil
promis
person
medicin
post
genom
era
mass
spectrometri
technolog
ms
grow
rapidli
past
sever
decad
sinc
john
bennet
fenn
koichi
tanaka
develop
new
soft
desorpt
method
made
mass
spectrometr
analys
biolog
macromolecul
possibl
technolog
wide
use
proteom
studi
abil
identifi
quantifi
target
molecul
eg
peptid
make
mass
spectrometri
method
popular
tool
diseas
marker
discoveri
diseas
marker
discoveri
mass
spectrometri
usual
combin
vari
sampl
separ
method
electrophoresi
differenti
ingel
electrophoresi
typic
procedur
mix
protein
pool
diseas
sampl
pool
control
separ
electrophoresi
individu
protein
band
spot
visual
differenti
band
spot
excis
follow
enzym
digest
eg
trypsin
digest
peptid
subject
mass
spectrometri
analysi
protein
identif
method
shen
et
al
identifi
potenti
marker
pancreat
adenocarcinoma
spectrum
marker
cover
antioxid
protein
chaperon
calciumbind
protein
catalyt
enzym
signal
transduct
protein
extracellular
matrix
protein
similarli
wang
et
al
identifi
differenti
express
protein
includ
novel
marker
associ
oral
squamou
cell
carcinoma
valid
one
eight
marker
name
use
immunostain
gene
silenc
studi
even
though
electrophoresi
improv
protein
separ
assist
identif
mass
spectrometri
discoveri
lowabund
diseas
marker
greatli
limit
poor
resolut
sensit
method
furthermor
pool
sampl
lose
import
inform
person
variat
diseas
marker
among
differ
individu
also
miss
protein
present
subset
sampl
popul
recent
improv
mass
spectrometri
techniqu
well
data
analysi
algorithm
enabl
analysi
complex
protein
sampl
current
liquid
chromatographi
lc
msm
use
electrospray
ioniz
esi
one
commonli
use
method
largescal
shotgun
proteom
studi
gelfre
method
mudpit
multidimension
protein
identif
technolog
popular
greatli
enhanc
detect
limit
improv
resolut
accuraci
mass
spectromet
make
technolog
use
diseas
marker
discoveri
lcmsm
ralhan
et
al
identifi
nonredund
protein
headandneck
squamou
cell
carcinoma
individu
cancer
sampl
compar
one
pool
normal
control
panel
three
best
perform
marker
achiev
sensit
specif
cancer
classif
recent
studi
identifi
ovarian
cancer
biomark
patient
ascit
sampl
lcmsm
also
yield
panel
known
novel
protein
marker
studi
demonstr
improv
ms
techniqu
enabl
research
search
biomark
unpool
sampl
also
could
lead
identif
larger
number
potenti
marker
due
improv
sensit
addit
protein
marker
identif
mass
spectrometri
also
capabl
identifi
metabolom
marker
metabolom
novel
field
studi
global
profil
metabolit
given
sampl
sinc
diseas
cancer
usual
uniqu
metabolom
overor
underpres
metabolit
could
serv
potenti
marker
diseas
moreov
certain
metabolit
cell
also
influenc
activ
larger
biomolecul
kinas
unpublish
data
therefor
identif
cancerspecif
metabolom
would
great
valu
current
multipl
metabolit
associ
variou
tumor
alanin
satur
lipid
ccm
glycin
lactat
myoinositol
nucleotid
pufa
taurin
surpris
list
grow
dramat
come
year
although
mass
spectrometri
power
tool
molecular
marker
identif
clinic
applic
technolog
diagnost
purpos
still
limit
mass
spectrometri
may
one
day
becom
platform
choic
detect
diseaseassoci
marker
howev
high
cost
mass
spectromet
well
lack
standard
method
prevent
adopt
clinician
diagnost
tool
moreov
high
level
molecular
complex
biolog
sampl
still
larg
obstacl
marker
identif
applic
remain
great
space
improv
mass
spectrometri
realiz
ultim
potenti
clinic
diseas
marker
import
effici
diagnosi
prognosi
treatment
diseas
therefor
identifi
marker
crucial
especi
diseas
high
mortal
rate
cancer
technolog
review
articl
uniqu
nich
diseas
marker
discoveri
protein
microarray
technolog
excel
find
protein
marker
especi
antibodi
marker
nextgener
parallel
sequenc
design
rna
geneticgenom
marker
discoveri
mass
spectrometri
special
identif
protein
marker
well
metabolom
marker
technolog
uniqu
advantag
limit
omic
inform
obtain
help
technolog
may
complement
lead
comprehens
view
diseas
fig
inform
greatli
expand
understand
etiolog
cours
human
diseas
result
effici
diagnosi
treatment
diseas
moreov
adopt
comprehens
omic
view
human
diseas
interest
discov
extent
system
interact
find
diseas
associ
certain
genet
marker
also
develop
specif
autoantibodi
certain
autoantigen
respons
actual
due
dysregul
specif
metabolit
transsplic
mrna
possibl
diseas
multipl
sclerosi
asthma
actual
caus
coordin
effect
genet
suscept
say
viral
infect
system
biolog
approach
diseas
marker
discoveri
still
infanc
alreadi
led
discoveri
mani
promis
genet
protein
marker
variou
diseas
addit
new
dimens
develop
applic
approach
may
revolution
field
interrog
addit
ome
methylgenom
kinom
virom
system
may
import
system
review
establish
complet
understand
effici
treatment
mani
diseas
